BIOMARKER:

MSI-H/dMMR + PD-L1 expression

Entrez ID:

Related biomarkers:

‹

›

MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Resistant: C4 – Case Studies	atezolizumab Resistant: C4 – Case Studies
MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	sacituzumab govitecan-hziy Resistant: C4 – Case Studies	sacituzumab govitecan-hziy Resistant: C4 – Case Studies
MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies